Asthma News and Research

RSS

Asthma is a common inflammatory disease affecting the airways that leads to shortness of breath, coughing and wheezing. Symptoms range from mild to severe but are generally manageable with appropriate treatment.

Lupin's Famotidine for Oral Suspension receives FDA approval

Lupin Pharmaceuticals, Inc. (LPI) announced today that it has received final approval from the US Food and Drug Administration (FDA) for its Famotidine for Oral Suspension (40 mg / 5 mL). Commercial shipments of the product have already commenced.

2 Jul 2010

Mutations in Siglec-8 gene may play role in asthma: Research

A gene that encodes a protein responsible for determining whether certain immune cells live or die shows subtle differences in some people with asthma, a team led by Johns Hopkins researchers reports in the June European Journal of Human Genetics.

1 Jul 2010

Sepracor announces preliminary results from OMNARIS HFA Phase III study for seasonal allergic rhinitis

Sepracor Inc. announced today the preliminary results of a large-scale, 671-patient Phase III study of OMNARIS® (ciclesonide) HFA, an aerosol nasal formulation of ciclesonide, for the treatment of seasonal allergic rhinitis (SAR) in adult and adolescent patients. In this study, OMNARIS HFA met its primary efficacy endpoint by demonstrating a statistically significant reduction versus placebo in the reflective total nasal symptom score averaged over a two-week treatment period.

1 Jul 2010

Calistoga Pharmaceuticals closes $40 million Series C financing

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced it has closed a $40 million Series C financing. The financing was led by Quogue Capital, LLC along with existing investors Alta Partners, Amgen Ventures, Frazier Healthcare and Three Arch Partners and new investor Latterell Venture Partners.

30 Jun 2010

Study implicates cytokine molecule IL-17 in low back pain associated with herniated discs

An immune cell known to cause chronic inflammation in autoimmune disorders has been identified as a possible culprit in low back pain associated with herniated discs, according to doctors at Duke University Medical Center.

29 Jun 2010

EDF praises New York State Assembly for passing legislation to reduce sulfur levels in heating oil

Environmental Defense Fund praised the New York State Assembly for passing legislation today to dramatically reduce sulfur levels in the commonly used #2 heating oil sold in the state. The State Senate passed the legislation last week and Governor Paterson is expected to sign it into law.

28 Jun 2010

Prescription Solutions introduces Clinical Vantage to improve health and well-being of members

Prescription Solutions, a leading pharmacy benefit management organization and a UnitedHealth Group company, has launched Clinical Vantage, a suite of clinical programs that enables clients to create specialized solutions to meet their particular needs to improve the health and well-being of members.

25 Jun 2010

HHS Secretary to speak about benefits of Affordable Care Act for women

Today, U.S. Secretary of Health and Human Services Secretary Kathleen Sebelius will speak to the National Partnership for Women and Families about how the Affordable Care Act will benefit women.

25 Jun 2010

HQC report presents different aspects of health care delivered in Saskatchewan hospitals

There's been little change over the last three years in how patients rate the care they receive in Saskatchewan hospitals, according to a report released today by the province's Health Quality Council. The report, entitled Quality Insight 2010, presents an overview of aspects of quality of care delivered in hospitals, in the community for people living with certain chronic diseases, and for seniors taking prescription drugs.

25 Jun 2010

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Merck today announced that the U.S. Food and Drug Administration (FDA) has approved DULERA® (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol, a new fixed-dose combination asthma treatment for patients 12 years of age and older. DULERA is not indicated for the relief of acute bronchospasm. DULERA combines an inhaled corticosteroid (mometasone furoate) with a long-acting beta2-agonist (formoterol fumarate).

24 Jun 2010

People with certain chitinase gene variants at increased risk of severe asthma attacks

Exposure to high levels of fungus may increase the risk of severe asthma attacks among people with certain chitinase gene variants, according to a study from Harvard Medical School, Harvard Pilgrim Health Care Institute and Brigham and Women's Hospital.

24 Jun 2010

Extract of French maritime pine tree bark reduces hay fever symptoms

An estimated 60 million people in the U.S. are affected by allergic rhinitis, commonly known as hay fever, according to the American Academy of Allergy Asthma and Immunology. Hay fever is an allergic inflammation of the nasal airways that causes itching, swelling, mucus production, hives and rashes. A study published in the June 14, 2010 issue of Phytotherapy Research demonstrates Pycnogenol- (pic-noj-en-all), an antioxidant plant extract derived from the bark of the French maritime pine tree, substantially improves the symptoms of hay fever.

24 Jun 2010

MSD enters collaboration with Adcock Ingram to co-promote, distribute products in South Africa

Merck (Merck is known as MSD outside the United States and Canada) today announced a strategic collaboration between MSD South Africa and Adcock Ingram, a publicly held South African company, to co-promote and distribute a number of established MSD products in South Africa. The products that will be jointly promoted by MSD and Adcock Ingram include over-the-counter (OTC) products and selected prescription medicines currently registered in South Africa by MSD and Schering-Plough.

24 Jun 2010

Entelos agree to the terms of non-exclusive perpetual license to Metabolism Physiolab platform for Pfizer

Entelos, Inc. announced today that it has agreed to the terms of a non-exclusive perpetual license to its Metabolism Physiolab platform for Pfizer Inc. The perpetual license will include access for Pfizer to Entelos' PhysioLab Modeler software and its PhysioLab Simulation Server.

24 Jun 2010

MAP Pharmaceuticals to present new analyses on LEVADEX from FREEDOM-301 Phase 3 clinical trial

MAP Pharmaceuticals, Inc. announced today it will present new analyses from the FREEDOM-301 Phase 3 clinical trial in a late breaker session at the 52nd Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, California on Friday, June 25 from 3:30 to 4:00 pm PT. The presentation will show that the Company's investigational LEVADEX™ orally inhaled migraine therapy was effective irrespective of when it was administered during a migraine cycle.

23 Jun 2010

Nuon study confirms potential utility of tranilast as uricosuric agent

Nuon Therapeutics, Inc., a privately held, clinical stage biopharmaceutical company, announced that results from clinical and preclinical studies demonstrating the ability of tranilast to reduce serum uric acid levels and monosodium urate crystal-induced inflammation - two important risk factors for gout - were presented at The European League Against Rheumatism (EULAR) 2010 Annual European Congress of Rheumatology in Rome, Italy, June 16-19, 2010.

22 Jun 2010

Improving health care for Saskatchewan patients remains a challenge: HQC report

In October 2008 the province's Health Quality Council released its first "state of health care quality" report, called Quality Insight. Key messages in that inaugural report were that limited access to timely data and the absence of an electronic health record were making it hard for HQC, health providers, and system leaders to improve health care for Saskatchewan patients.

22 Jun 2010

Asthmatics to suffer more this winter warn experts

Asthma sufferers in Australia have been warned about a bad cold and flu season ahead. 58 percent of the susceptible population is already experiencing asthma attacks since the start of the season according to The National Asthma Council Australia (NACA) on Monday. They went on to say that nearly half of this population is still not vaccinated against seasonal flu.

21 Jun 2010

Palatin reports preclinical study results of PL-3994 in respiratory tissue for asthma indications

Palatin Technologies, Inc. today announced results of preclinical studies in respiratory tissue with PL-3994. In rat, guinea pig and human tissues, PL-3994 produced potent relaxation of isolated airway smooth muscle, indicating that PL-3994 may be a potent bronchodilator in humans.

21 Jun 2010

New tobacco regulations and FDA rules authorized by Family Smoking and Prevention Act to be released

Starting tomorrow (June 22), new regulations and FDA rules authorized by the Family Smoking and Prevention Act will further limit the tobacco industry's ability to deceive consumers with misleading marketing and labeling that imply "light," "mild" or "low-tar" cigarettes are safer, as well as other practices that make products more appealing to youth.

21 Jun 2010

Asthma News and Research

Further Reading

Lupin's Famotidine for Oral Suspension receives FDA approval

Mutations in Siglec-8 gene may play role in asthma: Research

Sepracor announces preliminary results from OMNARIS HFA Phase III study for seasonal allergic rhinitis

Calistoga Pharmaceuticals closes $40 million Series C financing

Study implicates cytokine molecule IL-17 in low back pain associated with herniated discs

EDF praises New York State Assembly for passing legislation to reduce sulfur levels in heating oil

Prescription Solutions introduces Clinical Vantage to improve health and well-being of members

HHS Secretary to speak about benefits of Affordable Care Act for women

HQC report presents different aspects of health care delivered in Saskatchewan hospitals

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

People with certain chitinase gene variants at increased risk of severe asthma attacks

Extract of French maritime pine tree bark reduces hay fever symptoms

MSD enters collaboration with Adcock Ingram to co-promote, distribute products in South Africa

Entelos agree to the terms of non-exclusive perpetual license to Metabolism Physiolab platform for Pfizer

MAP Pharmaceuticals to present new analyses on LEVADEX from FREEDOM-301 Phase 3 clinical trial

Nuon study confirms potential utility of tranilast as uricosuric agent

Improving health care for Saskatchewan patients remains a challenge: HQC report

Asthmatics to suffer more this winter warn experts

Palatin reports preclinical study results of PL-3994 in respiratory tissue for asthma indications

New tobacco regulations and FDA rules authorized by Family Smoking and Prevention Act to be released

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News